225 related articles for article (PubMed ID: 22236880)
21. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
23. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.
Zhang Q; Wang HY; Wei F; Liu X; Paterson JC; Roy D; Mihova D; Woetmann A; Ptasznik A; Odum N; Schuster SJ; Marafioti T; Riley JL; Wasik MA
J Immunol; 2014 Mar; 192(6):2913-9. PubMed ID: 24523507
[TBL] [Abstract][Full Text] [Related]
25. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
26. Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice.
Wu X; Wang TW; Lessmann GM; Saleh J; Liu X; Chitambar CR; Hwang ST
J Invest Dermatol; 2015 Mar; 135(3):877-884. PubMed ID: 25371972
[TBL] [Abstract][Full Text] [Related]
27. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
28. Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression. The French Study Group on Cutaneous Lymphoma.
Courville P; Wechsler J; Thomine E; Vergier B; Fonck Y; Souteyrand P; Beylot-Barry M; Bagot M; Joly P
Br J Dermatol; 1999 Mar; 140(3):421-6. PubMed ID: 10233260
[TBL] [Abstract][Full Text] [Related]
29. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways.
Patil K; Kuttikrishnan S; Khan AQ; Ahmad F; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):382-399. PubMed ID: 34906723
[TBL] [Abstract][Full Text] [Related]
31. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
32. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
33. Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma.
Kume M; Kiyohara E; Matsumura Y; Koguchi-Yoshioka H; Tanemura A; Hanaoka Y; Taminato M; Tashima H; Tomita K; Kubo T; Watanabe R; Fujimoto M
Front Immunol; 2021; 12():651048. PubMed ID: 33859643
[TBL] [Abstract][Full Text] [Related]
34. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
36. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
37. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
38. Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis.
Oka T; Sugaya M; Takahashi N; Nakajima R; Otobe S; Kabasawa M; Suga H; Miyagaki T; Asano Y; Sato S
Acta Derm Venereol; 2017 Nov; 97(10):1172-1177. PubMed ID: 28597022
[TBL] [Abstract][Full Text] [Related]
39. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.
Krejsgaard T; Ralfkiaer U; Clasen-Linde E; Eriksen KW; Kopp KL; Bonefeld CM; Geisler C; Dabelsteen S; Wasik MA; Ralfkiaer E; Woetmann A; Odum N
J Invest Dermatol; 2011 Jun; 131(6):1331-8. PubMed ID: 21346774
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
